anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Control Group will be the group with remissive patients without the aforementioned comorbidities. We will assess whether comorbidities can worsen cognitive functions' impairment after the remission of the symptoms of COVID-19.
<P>PROBLEM TO BE SOLVED: To provide a medicinal effect mask to which herbs and drugs are added or impregnated to enable the mask to protect the respiratory organ for covering the body inside and taking in to cure or improve symptoms of diseases, poisoning, etc., not able to be treated by conventional drugs and injection.  <P>SOLUTION: This medicinal effect mask is equipped with an attached inhaling part 5 to which micro-powdered drugs and herbs 2 are added or impregnated by sublimation, vaporization, and liquefaction for use. On the other hand, the micro-powdered drugs and herbs are filled into an artificial respirator which is connected to the attached inhaling part 5 of the mask main body 1 for use. A micro-volume of the micro-powdered drugs and herbs is continuously inhaled through an inhaling part 4 to cover or be taken in the upper and lower respiratory tracts. A dry processing sheet to block and obstruct water, moisture, and unpleasant feeling in the mask main body 1 is attached. A material not to obstruct respiration is used for the mask main body. An elastic material 6 such as a rubber string etc., can be used for wearing means for engaging the mask main body 1, or the mask main body 1 is made of an elastic material and an ear hook 7 with a detachable hook shape protection part 8 for hooking on the ear is available.  <P>COPYRIGHT: (C)2004,JPO
In the production of transmissible gastro-enteritis (T.G.E.) virus vaccine, virulent particles of the virus are inoculated into a first tissue culture, the virus is incubated therein for a period up to 24 hours, preferably for from 6 to 14 hours, the viral particles are removed from the culture and inoculated into one or more further tissue cultures, and the incubation and inoculation into further tissue culture or cultures is repeated one or more times.  The virus is obtained from the mucosa of the intestinal tracts of infected pigs.  Tissues of swine, sheep, cattle, dogs, ferrets and cats may be employed; however, it is preferred to use dog kidney cells for each tissue culture.  The incubation of the virulent virus is carried out at 35 DEG  to 38  DEG C. The propagation of the virus may be continued until it is rendered avirulent.  An inactivated vaccine may be prepared by combining a virus-containing culture with a stabilizing menstrum and incubating at 25 DEG  C. for five days.  The vaccine can be stored at a low temperature or freeze-dried.  Sows and their nursing pigs can be immunized against transmissible gastro-enteritis virus by injecting the virus vaccine into the pregnant sow six weeks before farrowing, thereby stimulating the production of anti-bodies which protect the sow, and nursing the pigs on the sow thereby protecting them against the virus by way of anti-bodies passed in the milk.ALSO:In the production of transmissible gastroenteritis (T.G.E.) virus vaccine, virulent particles of the virus are inoculated into a first tissue culture, the virus is incubated therein for a period up to 24 hours, preferably for from 6 to 14 hours, the viral particles are removed from the culture and inoculated into one or more further tissue cultures, and the incubation and inoculation into further tissue culture or cultures is repeated one or more times.  The virus is obtained from the mucosa of the p  intestinal tracts of infected pigs.  Tissues of swine, sheep, cattle, dogs, ferrets and cats may be employed; however, it is preferred to use dog kidney cells for each tissue culture.  The incubation of the virulent virus is carried out at 35 DEG  to 38 DEG C. The propagation of the virus may be continued until it is rendered avirulent.  An inactivated vaccine may be prepared by combining a virus-containing culture with a stabilizing menstrum and incubating at 25 DEG C for five days.  The vaccine can be stored at a low temperature or freeze-dried.  Sows and their nursing pigs can be immunized against transmissible gastroenteritis virus by injecting the virus vaccine into the pregnant sow six weeks before farrowing, thereby stimulating the production of antibodies which protect the sow, and nursing the pigs on the sow thereby protecting them against the virus by way of antibodies passed in the milk.
Cardiovascular disease is now a major health concern among persons with HIV infection. Our general hypothesis is that HIV-mediated inflammation and injury to vascular surfaces up-regulates thrombotic pathways and leads to damage of blood vessels that is promotes development of cardiovascular disease. HIV drug treatment (antiretroviral therapy; ART) may reduce inflammation and vessel injury via suppression of HIV replication, but also includes side effects or toxicity that may increase risk for cardiovascular disease in and of itself. In this context, additional anti-inflammatory and anti-thrombotic medications are needed. Acetylsalicylic acid (aspirin) is an excellent candidate and is commonly used for secondary prevention of cardiovascular events in the general population, but few studies have examined it's use in persons with HIV infection. The goal of this study is to generate pilot data regarding changes in measures of cardiovascular risk, as determined by reductions in inflammatory and thrombotic blood markers and a decrease in blood vessel injury (blood markers) and dysfunction (assessment of arterial elasticity), that occur after starting ART and aspirin among persons with HIV infection.
Group 2 will not receive any gum. They will be asked to swallow twice and have no other intervention.
Caution should be exercised in handling and preparing Paraplatin ® (carboplatin) injection. Several guidelines on this subject have been published. 1-4

To minimize the risk of dermal exposure, always wear impervious gloves when handling vials containing Paraplatin ® (carboplatin) injection. If Paraplatin ® (carboplatin) injection contacts the skin, immediately wash the skin thoroughly with soap and water. If Paraplatin ® (carboplatin) injection contacts mucous membranes, the membranes should be flushed immediately and thoroughly with water. More information is available in the references listed below.
The purpose of this research study is to design, implement, and evaluate a community level, socio-ecological based CVD prevention intervention using a participatory approach for women in a homogeneous ultra-Orthodox Jewish Hasidic community in Israel. A quasi-experimental, pre-post study design will be utilized, where all community participants will be exposed to intervention components. Pre and post samples will be selected through randomized cluster sampling of pre-existing community groups (n=239 ). Intervention components will be designed through qualitative and quantitative data collection (focus groups, interviews, and questionnaires) from the target population and implementation will be conducted in partnership with community organizations. Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities. It is hypothesized that ultra-Orthodox Jewish Hasidic women exposed to this community intervention will have improved healthy eating behaviors, reduced unhealthy eating behaviors, increased engagement in physical activity and sleep, and reduced risk for obesity (weight, BMI).
Osteoarthritis (OA) is a degenerative joint disorder that is distinguished by inflammation and chronic cartilage damage. Interleukin-1β (IL-1β) is a proinflammatory cytokine that plays an important role in the catabolic processes that underlie the pathogenesis of OA. In this study, we investigate the therapeutic efficacy of exosomes derived from untreated bone-marrow-derived mesenchymal stem cells (BMMSC-Exo) and those treated with cinnamaldehyde (BMMSC-CA-Exo) for preventing the in vitro catabolic effects of IL-1β on chondrocytes. We stimulated chondrocytes with IL-1β to mimic the inflammatory microenvironment of OA. We then treated these chondrocytes with BMMSC-Exo and BMMSC-CA-Exo isolated via an aqueous two-phase system and evaluated their effects on the key cellular processes using molecular techniques. Our findings revealed that treatment with BMMSC-Exo reduces the catabolic effects of IL-1β on chondrocytes and alleviates inflammation. However, further studies directly comparing treatments with BMMSC-Exo and BMMSC-CA-Exo are needed to determine if CA preconditioning can provide additional anti-inflammatory benefits to the exosomes beyond those of CA preconditioning or treatment with regular BMMSC-Exo. Through a comprehensive molecular analysis, we elucidated the regulatory mechanisms underlying this protective effect. We found a significant downregulation of proinflammatory signaling pathways in exosome-infected chondrocytes, suggesting the potential modulation of the NF-κB and MAPK signaling cascades. Furthermore, our study identified the molecular cargo of BMMSC-Exo and BMMSC-CA-Exo, determining the key molecules, such as anti-inflammatory cytokines and cartilage-associated factors, that may contribute to their acquisition of chondroprotective properties. In summary, BMMSC-Exo and BMMSC-CA-Exo exhibit the potential as therapeutic agents for OA by antagonizing the in vitro catabolic effects of IL-1β on chondrocytes. The regulation of the proinflammatory signaling pathways and bioactive molecules delivered by the exosomes suggests a multifaceted mechanism of action. These findings highlight the need for further investigation into exosome-based therapies for OA and joint-related diseases.
The present invention relates to a pharmaceutical composition for preventing or treating hyperphosphatemia and kidney disease and a health functional food for improving hyperphosphatemia and kidney disease by using a  Lactobacillus  sp .  KCCM 11826P strain that is superior in terms of phosphorus absorption ability. Having excellent phosphorous absorption ability, the  Lactobacillus  sp .  KCCM 11826P selected according to the present invention can greatly inhibit intestinal phosphorous absorption by the human body. In addition, the strain can be used as an alternative of a conventional calcium-based phosphate binder so as to minimize side effects attributed to an increase in blood calcium level, with the consequent effective prevention or treatment of hyperphosphatemia and kidney disease complications. Further, the  Lactobacillus  sp .  KCCM 11826P selected according to the present invention can be provided for ingestion at lower cost compared to a conventional phosphate binder, and is far more convenient to ingest than a conventional phosphate binder since the strain can be developed into yogurt, powder, a nutritional food for patients, etc. in consideration of strain characteristics.
OBJECTIVE: Determination of the real-world performance of a health care system in the treatment of status epilepticus (SE).
METHODS: Prospective, multicenter population-based study of SE in Auckland, New Zealand (NZ) over 1 year, with data recorded in the EpiNet database. Focus on treatment patterns and determinants of SE duration and 30-day mortality. The incidence, etiology, ethnic discrepancies, and seizure characteristics of this cohort have been published previously.
RESULTS: A total of 365 patients were included in this treatment cohort; 326 patients (89.3%) were brought to hospital because of SE, whereas 39 patients (10.7%) developed SE during a hospital admission for another reason. Overall, 190 (52.1%) had a known history of epilepsy and 254 (70.0%) presented with SE with prominent motor activity. The mean Status Epilepticus Severity Score (STESS) was 2.15 and the mean SE duration of all patients was 44 min. SE self-terminated without any treatment in 84 patients (22.7%). Earlier administration of appropriately dosed benzodiazepine in the pre-hospital setting was a major determinant of SE duration. Univariate analysis demonstrated that mortality was significantly higher in older patients, patients with longer durations of SE, higher STESS, and patients who developed SE in hospital, but these did not maintain significance with multivariate analysis. There was no difference in the performance of the health care system in the treatment of SE across ethnic groups.
SIGNIFICANCE: When SE was defined as 10 continuous minutes of seizure, overall mortality was lower than expected and many patients had self-limited presentations for which no treatment was required. Although there were disparities in the incidence of SE across ethnic groups there was no difference in treatment or outcome. The finding highlights the benefit of a health care system designed to deliver universal health care.
PURPOSE: An antibacterial and antifungal peptide with four times repeated lysine and tryptophan residues is provided to have excellent antibacterial activity against gram-negative bacteria, gram-positive bacteria, and antibiotic-resistant strains, and to be used in pharmaceutical compositions, cosmetic compositions, agrochemicals, and preservatives for foods, cosmetics, and pharmaceutical products. CONSTITUTION: An antibacterial and antifungal peptide has four times repeated lysine and tryptophan residues. The peptide has an amino acid sequence of sequence number 3. The peptide has an antibacterial activity against gram-positive bacteria which are selected from the group consisting of Bacillus subtilis, Staphylococcus aureus, and Listeria monocytogenes. An antibacterial and antifungal pharmaceutical composition contains the peptide as an active ingredient. [Reference numerals] (AA) Sequence number 1; (BB) Sequence number 2; (CC) Sequence number 3; (DD) Sequence number 4
In the NSABP P-1 trial, the percentage of women at least 65 years of age was 16%. Women at least 70 years of age accounted for 6% of the participants. A reduction in breast cancer incidence was seen among participants in each of the subsets. A total of 28 and 10 invasive breast cancers were seen among participants 65 and older in the placebo and tamoxifen groups, respectively. Across all other outcomes, the results in this subset reflect the results observed in the subset of women at least 50 years of age. No overall differences in tolerability were observed between older and younger patients (see CLINICAL PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer Incidence in High Risk Women).

In the NSABP B-24 trial, the percentage of women at least 65 years of age was 23%. Women at least 70 years of age accounted for 10% of participants. A total of 14 and 12 invasive breast cancers were seen among participants 65 and older in the placebo and tamoxifen groups, respectively. This subset is too small to reach any conclusions on efficacy. Across all other endpoints, the results in this subset were comparable to those of younger women enrolled in this trial. No overall differences in tolerability were observed between older and younger patients.
Melittin, a principal constituent of honeybee venom, exhibits diverse biological effects, encompassing anti-inflammatory capabilities and neuroprotective actions against an array of neurological diseases. In this study, we probed the prospective protective influence of melittin on cerebral ischemia, focusing on its anti-inflammatory activity. Mechanistically, we explored whether monocyte chemotactic protein-induced protein 1 (MCPIP1, also known as ZC3H12A), a recently identified zinc-finger protein, played a role in melittin-mediated anti-inflammation and neuroprotection. Male C57/BL6 mice were subjected to distal middle cerebral artery occlusion to create a focal cerebral cortical ischemia model, with melittin administered intraperitoneally. We evaluated motor functions, brain infarct volume, cerebral blood flow, and inflammatory marker levels within brain tissue, employing quantitative real-time polymerase chain reaction, enzyme-linked immunosorbent assays, and western blotting. In vitro, an immortalized BV-2 microglia culture was stimulated with lipopolysaccharide (LPS) to establish an inflammatory cell model. Post-melittin exposure, cell viability, and cytokine expression were examined. MCPIP1 was silenced using siRNA in LPS-induced BV-2 cells, with the ensuing nuclear translocation of nuclear factor-κB assessed through cellular immunofluorescence. In vivo, melittin enhanced motor functions, diminished infarction, fostered blood flow restoration in ischemic brain regions, and markedly inhibited the expression of inflammatory cytokines (interleukin-1β, interleukin-6, tumor necrosis factor-α, and nuclear factor-κB). In vitro, melittin augmented MCPIP1 expression in LPS-induced BV-2 cells and ameliorated inflammation-induced cell death. The neuroprotective effect conferred by melittin was attenuated upon MCPIP1 knockdown. Our findings establish that melittin-induced tolerance to ischemic injury is intrinsically linked with its anti-inflammatory capacity. Moreover, MCPIP1 is, at the very least, partially implicated in this process.
UNLABELLED: Gut dysbiosis is closely related to dysregulated microRNAs (miRNAs) in the intestinal epithelial cells, which plays an important role in the pathogenesis of Crohn's disease (CD). We investigated the relationship between fecal gut microbiome (GM) and intestinal tissue miRNAs in different stages of pediatric CD. Metagenomic analysis and miRNA sequencing were conducted to examine the GM and intestinal miRNA profiles of CD patients before and after clinical induction therapy and the controls. Twenty-seven newly diagnosed, therapy-naïve pediatric patients with active CD and 11 non-inflammatory bowel disease (IBD) controls were recruited in this study. Among CD patients, 11 patients completed induction treatment and reached clinical remission. Both GM and miRNA profiles were significantly changed between CD patients and controls. Seven key bacteria were identified at species level including Defluviitalea raffinosedens, Thermotalea metallivorans, Roseburia intestinalis, Dorea sp. AGR2135, Escherichia coli, Shigella sonnei, and Salmonella enterica, the exact proportions of which were further validated by real-time quantitative PCR analysis. Eight key miRNAs were also identified including hsa-miR-215-5p, hsa-miR-194-5p, hsa-miR-12135, hsa-miR-509-3-5p, hsa-miR-212-5p, hsa-miR-4448, hsa-miR-501-3p, and hsa-miR-503-5p. The functional enrichment analysis of differential miRNAs indicated the significantly altered cyclin protein, cyclin-dependent protein, and cell cycle pathway. The close interactions between seven key bacteria and eight key miRNAs were further investigated by miRNA target prediction. The association between specific miRNA expressions and key gut bacteria at different stages of CD supported their important roles as potential molecular biomarkers. Understanding the relationship between them will help us to explore the molecular mechanisms of CD.
IMPORTANCE: Since previous studies have focused on the change of the fecal gut microbiome and intestinal tissue miRNA in pediatric Crohn's disease (CD), the relationship between them in different stages is still not clear. This is the first study to explore the gut microbiota and miRNA and their correlations with the Pediatric Crohn's Disease Activity Index (PCDAI). Crohn's Disease Endoscopic Index of Severity (CDEIS), and calprotectin, by applying two omics approach in three different groups (active CD, CD in remission with exclusive enteral nutrition or infliximab induction therapy, and the healthy controls). Both gut microbiome structure and the miRNA profiles were significantly changed in the different stage of CD. Seven key gut microbiome at species and eight key miRNAs were found, and their close interactions were further fully investigated by miRNA target prediction.
NEW MATERIAL:The compound of formula I. USE:Pharmaceuticals having anti-inflammatory effect. PREPARATION:The compound of formula I can be prepared by the methylcarbamoylation of the hydroxyl group of beta-hydroxysulfoxide of formula II. The methylcarbamoylation is carried out by reacting with methyl isocyanate in an inert organic solvent, e.g. a benzene-type solvent such as benzene, in the presence of a tertiary organic amine usually at normal temperature. The compound of formula I is separated from the reaction mixture by distilling out the reaction solvent and crystallizing the objective compound with a crystallization solvent such as benzene-hexane. The starting compound of formula II is available as individual diastereomer or their mixture. For example, the compound of formula III can be prepared stereo-selectively by reducing alpha-(p-tolylthio) isovalerophenone with NaBH4, and oxidizing the resultant beta-hydroxysulfide of formula IV with m-chloroperbenzoic acid.
Participants will receive sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks in the placebo-controlled treatment period. After completion of the placebo-controlled treatment period, participants will continue to receive sotatercept SC at a dose level of 0.3 mg/kg Q3W in an extension period for up to 18 months.
A baculovirus expression system capable of producing foreign gene proteins at high levels. The system involves the production of a recombinant baculovirus containing a modified foreign gene between the polyhedrin gene promoter region and the transcription termination signal of the polyhedrin structural gene. The modified foreign gene comprises a putative ribosome binding site immediately upstream of the foreign gene coding sequence, i.e. without any intervening non-coding sequences. The putative ribosome binding site is preferably properly positioned without the intervening sequences by a crossover linker mutagenesis procedure before the modified foreign gene is introduced into the virus. The putative ribosome binding site preferably comprises at least the final four nucleotides of the sequence ACCTATAAAT immediately upstream of the translation initiation codon (ATG) of the foregin gene. The system is capable of producing foreign gene proteins (when insect cells are infected with the recombinant virus) at high levels, even in the case of those genes which expressed only at low or intermediate levels in prior recombinant baculovirus systems.
PURPOSE: A web based manifold research system is provided to improve the protection and security for a main modification item by setting a modification permission range by user according to user recognition. CONSTITUTION: A data server (50) stores and manages data. A web server (30) is connected to the data server. The web server controls data of the data server. A plurality of terminals (10) is communication-capably connected to the web server. The plurality of terminals implements a screen in a web page style by making an attribute corresponding to a data item stored in the data server by the web server. [Reference numerals] (10) Terminal; (30) Web server; (50) Data server; (AA) Procedure
Patients receive ICE comprising ifosfamide IV and carboplatin IV once on day 2 and etoposide IV over 1 hour once daily on days 1-3. Patients then receive ifosfamide IV twice on day 15, carboplatin IV once on day 17 and etoposide IV over 1 hour twice daily on days 15-17.